Sustained minimal residual disease (MRD) negativity may predict long-term outcomes in relapsed/refractory multiple myeloma (RRMM), according to a recent analysis of the POLLUX and CASTOR studies. In addition, daratumumab-based combinations led to higher rates of sustained MRD negativity compared with the standard of care.
Although patients with MM have had improved response rates due to combination therapies in recent years, the majority relapse and must undergo further therapy. The authors of the new study, published in the Journal of Clinical Oncology, assessed sustained MRD negativity and patient outcomes based on data from POLLUX and CASTOR, which represent the largest set of MRD data collected from RRMM patients.
The phase 3 POLLUX study compared daratumumab, lenalidomide, and dexamethasone (D-Rd) with lenalidomide and dexamethasone (Rd) in RRMM. CASTOR, also a phase 3 study, compared daratumumab, bortezomib, and dexamethasone (D-Vd) with bortezomib and dexamethasone (Vd) in RRMM. Overall, 569 patients in POLLUX and 498 in CASTOR were included in the new analysis.
